Cargando…

Investigation of the Underlying Mechanism of Huangqi-Dangshen for Myasthenia Gravis Treatment via Molecular Docking and Network Pharmacology

The herbal pairing of Huangqi and Dangshen (HD) is traditional Chinese herbal medicine and has been widely used in China, especially to treat myasthenia gravis (MG). However, the mechanism of HD on MG is unclear. Aim of the Study. This study aims to investigate HD's possible role in MG treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Miao, Lu, Jing, Chen, Yujuan, Zhang, Dongmei, Huang, Wei, Shi, Mengqi, Zhang, Yibin, Wu, Tong, Chen, Zhuming, Wu, Lei, Chen, Xinzhi, Wang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935813/
https://www.ncbi.nlm.nih.gov/pubmed/36818231
http://dx.doi.org/10.1155/2023/5301024
_version_ 1784890094082064384
author Liu, Miao
Lu, Jing
Chen, Yujuan
Zhang, Dongmei
Huang, Wei
Shi, Mengqi
Zhang, Yibin
Wu, Tong
Chen, Zhuming
Wu, Lei
Chen, Xinzhi
Wang, Jian
author_facet Liu, Miao
Lu, Jing
Chen, Yujuan
Zhang, Dongmei
Huang, Wei
Shi, Mengqi
Zhang, Yibin
Wu, Tong
Chen, Zhuming
Wu, Lei
Chen, Xinzhi
Wang, Jian
author_sort Liu, Miao
collection PubMed
description The herbal pairing of Huangqi and Dangshen (HD) is traditional Chinese herbal medicine and has been widely used in China, especially to treat myasthenia gravis (MG). However, the mechanism of HD on MG is unclear. Aim of the Study. This study aims to investigate HD's possible role in MG treatment. Materials and Methods. The TCMSP database was used to identify the active chemicals and their targets. The GeneCards, DisGeNET, and OMIM databases were used to search for MG-related targets. The STRING database was employed in order to identify the common PPI network targets. We next utilised Cytoscape 3.8.2 for target identification and the DAVID database for gene ontology (GO) function analysis as well as Encyclopaedia of Genomes (KEGG) pathway enrichment analysis on the selected targets. The AutoDock Vina software was used to test the affinity of essential components with the hub gene before concluding that the primary targets were corrected through molecular docking. Results. 41 active compounds were screened from HD, and the number of putative-identified target genes screened from HD was 112. There were 21 target genes that overlapped with the targets of MG, which were postulated to be potential treatment targets. Through further analysis, the results showed that the active compounds from HD (such as 7-methoxy-2-methylisoflavone, quercetin, luteolin, Kaempferol, and isorhamnetin) may achieve the purpose of treating MG by acting on some core targets and related pathways (such as EGFR, FOS, ESR2, MYC, ESR1, CASP3, and IL-6). Molecular docking findings demonstrated that these active molecules have a near-perfect ability to attach to the primary targets. Conclusion. Through network pharmacology, the findings in this study provide light on the coordinated action of several HD formula components, targets, and pathways. It provided a theoretical basis for further study of HD pharmacological action.
format Online
Article
Text
id pubmed-9935813
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-99358132023-02-18 Investigation of the Underlying Mechanism of Huangqi-Dangshen for Myasthenia Gravis Treatment via Molecular Docking and Network Pharmacology Liu, Miao Lu, Jing Chen, Yujuan Zhang, Dongmei Huang, Wei Shi, Mengqi Zhang, Yibin Wu, Tong Chen, Zhuming Wu, Lei Chen, Xinzhi Wang, Jian Evid Based Complement Alternat Med Research Article The herbal pairing of Huangqi and Dangshen (HD) is traditional Chinese herbal medicine and has been widely used in China, especially to treat myasthenia gravis (MG). However, the mechanism of HD on MG is unclear. Aim of the Study. This study aims to investigate HD's possible role in MG treatment. Materials and Methods. The TCMSP database was used to identify the active chemicals and their targets. The GeneCards, DisGeNET, and OMIM databases were used to search for MG-related targets. The STRING database was employed in order to identify the common PPI network targets. We next utilised Cytoscape 3.8.2 for target identification and the DAVID database for gene ontology (GO) function analysis as well as Encyclopaedia of Genomes (KEGG) pathway enrichment analysis on the selected targets. The AutoDock Vina software was used to test the affinity of essential components with the hub gene before concluding that the primary targets were corrected through molecular docking. Results. 41 active compounds were screened from HD, and the number of putative-identified target genes screened from HD was 112. There were 21 target genes that overlapped with the targets of MG, which were postulated to be potential treatment targets. Through further analysis, the results showed that the active compounds from HD (such as 7-methoxy-2-methylisoflavone, quercetin, luteolin, Kaempferol, and isorhamnetin) may achieve the purpose of treating MG by acting on some core targets and related pathways (such as EGFR, FOS, ESR2, MYC, ESR1, CASP3, and IL-6). Molecular docking findings demonstrated that these active molecules have a near-perfect ability to attach to the primary targets. Conclusion. Through network pharmacology, the findings in this study provide light on the coordinated action of several HD formula components, targets, and pathways. It provided a theoretical basis for further study of HD pharmacological action. Hindawi 2023-02-08 /pmc/articles/PMC9935813/ /pubmed/36818231 http://dx.doi.org/10.1155/2023/5301024 Text en Copyright © 2023 Miao Liu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liu, Miao
Lu, Jing
Chen, Yujuan
Zhang, Dongmei
Huang, Wei
Shi, Mengqi
Zhang, Yibin
Wu, Tong
Chen, Zhuming
Wu, Lei
Chen, Xinzhi
Wang, Jian
Investigation of the Underlying Mechanism of Huangqi-Dangshen for Myasthenia Gravis Treatment via Molecular Docking and Network Pharmacology
title Investigation of the Underlying Mechanism of Huangqi-Dangshen for Myasthenia Gravis Treatment via Molecular Docking and Network Pharmacology
title_full Investigation of the Underlying Mechanism of Huangqi-Dangshen for Myasthenia Gravis Treatment via Molecular Docking and Network Pharmacology
title_fullStr Investigation of the Underlying Mechanism of Huangqi-Dangshen for Myasthenia Gravis Treatment via Molecular Docking and Network Pharmacology
title_full_unstemmed Investigation of the Underlying Mechanism of Huangqi-Dangshen for Myasthenia Gravis Treatment via Molecular Docking and Network Pharmacology
title_short Investigation of the Underlying Mechanism of Huangqi-Dangshen for Myasthenia Gravis Treatment via Molecular Docking and Network Pharmacology
title_sort investigation of the underlying mechanism of huangqi-dangshen for myasthenia gravis treatment via molecular docking and network pharmacology
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935813/
https://www.ncbi.nlm.nih.gov/pubmed/36818231
http://dx.doi.org/10.1155/2023/5301024
work_keys_str_mv AT liumiao investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT lujing investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT chenyujuan investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT zhangdongmei investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT huangwei investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT shimengqi investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT zhangyibin investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT wutong investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT chenzhuming investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT wulei investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT chenxinzhi investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology
AT wangjian investigationoftheunderlyingmechanismofhuangqidangshenformyastheniagravistreatmentviamoleculardockingandnetworkpharmacology